Shanghai Biomabs Pharmaceuticals Co Ltd Report issue

Government Phase 1 Phase 3
Founded: China

Organization Overview

First Clinical Trial
2009
NCT01550055
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai Biomabs Pharmaceutical Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 3)

Colorectal Neoplasms (Phase 3)

Osteoporosis (Phase 3)

Osteoporosis, Postmenopausal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 12